Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis.
Author(s): Khoshhal K, Mukhtar I, Clark P, Jarvis J, Letts M, Splinter W
Affiliation(s): Children's Hospital of Eastern Ontario, University of Ottawa, Canada.
Publication date & source: 2003-09, J Pediatr Orthop., 23(5):661-4.
Publication type: Clinical Trial; Randomized Controlled Trial
Aprotinin is a proteinase inhibitor with antifibrinolytic properties that has found widespread application during cardiac surgical procedures due to its ability to decrease blood loss and transfusion requirements. Recently it has been used by orthopedic surgeons in hip replacement and other major surgeries except for scoliosis surgery, which is known to be associated with major blood loss. To evaluate the effect of aprotinin in reducing blood loss during spinal fusion surgery for idiopathic scoliosis, a double-blind randomized prospective clinical study was performed. Forty-three patients with idiopathic scoliosis underwent spinal fusion and instrumentation and were divided randomly into two groups. Fifteen patients received aprotinin, whereas 28 patients received placebo. The aprotinin group had less blood loss than the placebo group. The transfusion requirement was less in the aprotinin group than the placebo group. Although the difference was not significant statistically, the benefit of aprotinin in reducing blood loss in spinal surgery for idiopathic scoliosis was consistent.